~0 spots leftby Apr 2025

Sleep Management for Nicotine Addiction

Recruiting in Palo Alto (17 mi)
Karen Cropsey, Psy.D. - Center for ...
Overseen byKaren Cropsey, Psy.D.
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: University of Alabama at Birmingham
No Placebo Group

Trial Summary

What is the purpose of this trial?

The number one preventable cause of death in the world is tobacco use. Cigarette smoking in particular, costs an estimated $300 billion due to expenses related to medical care and lost productivity. Despite similar smoking prevalence rates, blacks suffer disproportionately from smoking-related harms compared to whites.Sleep disparities such as shortened sleep duration, shorter circadian periodicity, earlier chronotype, and increased variability of sleep timing have been reported more frequently in blacks compared to whites. Given that poor sleep quality predicts relapse from smoking cessation programs, particularly among socioeconomically disadvantaged adults, sleep deficiencies and irregular timing of sleep may impact smoking craving and withdrawal symptoms over the course of the 24-hour day. Surprisingly, few studies have examined these temporal patterns of smoking and craving, and none with regard to sleep disruption, chronotype or racial disparities. A better understanding of these factors may explain heterogeneity within the smoking population, especially in minorities. Thus, the purpose of this proposal is to test the central hypothesis that the impact of chronotype and impaired sleep on cigarette usage as well as smoking dependence, urge/craving, and withdrawal depends on race.

Do I need to stop taking my current medications to join the trial?

The trial does not specify if you need to stop taking your current medications, but if you are taking psychiatric medications, pain medications (like opioids), or sleep medications (such as Ambien, trazodone, melatonin, or CBD products), you cannot participate in Sub-study 3.

What data supports the idea that Sleep Management for Nicotine Addiction is an effective treatment?

The available research shows that addressing sleep problems can help improve smoking cessation outcomes. Sleep issues are common during nicotine withdrawal and can make quitting harder. By focusing on sleep, treatments like dual orexin receptor antagonists (DORAs) can reduce withdrawal symptoms and nicotine cravings, making it easier to quit smoking. This approach is promising because it targets both sleep and addiction, unlike other treatments that might worsen sleep problems. Additionally, studies show that nicotine replacement can improve sleep quality during withdrawal, which supports the idea that managing sleep can aid in quitting smoking.12345

What safety data exists for sleep management in nicotine addiction treatment?

The safety data for sleep management in nicotine addiction treatment includes the use of dual orexin receptor antagonists (DORAs) like suvorexant and lemborexant, which have a milder adverse event profile compared to previous insomnia treatments. Nicotine replacement therapy has been shown to improve sleep quality post-cessation, despite withdrawal-related sleep disturbances. Studies have also compared the effects of different nicotine patch durations on sleep, indicating that nicotine presence or withdrawal can affect sleep patterns.15678

Is the drug used in the Sleep Management for Nicotine Addiction trial a promising treatment?

Yes, the drug used in the trial, which targets sleep issues with dual orexin receptor antagonists (DORAs), is promising. It helps reduce nicotine cravings and withdrawal difficulties by improving sleep, which is often disturbed during smoking cessation. This approach could make it easier for people to quit smoking and stay smoke-free.13589

Research Team

Karen Cropsey, Psy.D. - Center for ...

Karen Cropsey, Psy.D.

Principal Investigator

University of Alabama at Birmingham

Eligibility Criteria

This trial is for adults over 18 who can read and speak English, identify as non-Hispanic African American or white, and live in Alabama. It's for daily smokers (5+ cigarettes a day for the past year) or non-smokers (less than 100 cigarettes lifetime, none in the last year).

Inclusion Criteria

Sub-Study 1
Able to read and speak English
I am a daily smoker or I have never smoked more than 100 cigarettes in my life.
See 3 more

Treatment Details

Interventions

  • Sleep extension condition (Behavioural Intervention)
  • Sleep restriction condition (Behavioural Intervention)
Trial OverviewThe study examines how sleep patterns affect cigarette cravings and withdrawal by comparing two conditions: extending participants' sleep time versus restricting it. The focus is on racial differences in these effects.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Sleep RestrictionExperimental Treatment1 Intervention
4 hours time in bed (1 am to 5 am)
Group II: Sleep ExtensionExperimental Treatment1 Intervention
10 hours time in bed (10 pm to 8 am)

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+
Kierstin Kennedy profile image

Kierstin Kennedy

University of Alabama at Birmingham

Chief Medical Officer since 2022

MD

S. Dawn Bulgarella profile image

S. Dawn Bulgarella

University of Alabama at Birmingham

Chief Executive Officer since 2023

BSc in Commerce and Business Administration from the University of Alabama, MS in Health Administration from the University of Alabama at Birmingham

National Institute on Drug Abuse (NIDA)

Collaborator

Trials
2,658
Recruited
3,409,000+
Dr. Nora Volkow profile image

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Executive Officer since 2003

MD from National Autonomous University of Mexico

Dr. Nora Volkow profile image

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Medical Officer since 2003

MD from National Autonomous University of Mexico

University of Oklahoma

Collaborator

Trials
484
Recruited
95,900+
Dr. Scott Rollins profile image

Dr. Scott Rollins

University of Oklahoma

Chief Executive Officer since 2016

PhD in Immunology from the University of Oklahoma

Dr. Ondria Gleason profile image

Dr. Ondria Gleason

University of Oklahoma

Chief Medical Officer

MD from the University of Oklahoma College of Medicine

Findings from Research

Current smoking cessation medications often worsen sleep problems, which can hinder quitting success, highlighting the need for new approaches.
Dual orexin receptor antagonists (DORAs) like suvorexant and lemborexant may improve smoking cessation outcomes by alleviating withdrawal symptoms and reducing cravings, while also having a better safety profile than traditional insomnia treatments.
Dual Orexin Receptor Antagonists (DORAs) as an Adjunct Treatment for Smoking Cessation.Hamidovic, A.[2022]
Despite a national decline in tobacco use to 15.1%, high-risk, low-income populations still show smoking rates as high as 50%, highlighting the need for more effective smoking cessation strategies.
This review suggests that addressing sleep disturbances, which are common during nicotine withdrawal, could enhance the effectiveness of existing smoking cessation treatments, making sleep therapy a promising adjunctive approach.
Sleep as a Target for Optimized Response to Smoking Cessation Treatment.Patterson, F., Grandner, MA., Malone, SK., et al.[2020]
In a study of 20 dependent smokers, the 24-hour nicotine patch was found to be more effective than the 16-hour patch in reducing morning smoking urges and enhancing sleep quality, particularly by increasing slow wave sleep.
The 24-hour patch not only alleviated smoking urges more effectively but also improved morning alertness, suggesting that continuous nicotine delivery does not disrupt sleep but may actually enhance restorative sleep.
Comparison of the effects of a 24-hour nicotine patch and a 16-hour nicotine patch on smoking urges and sleep.Aubin, HJ., Luthringer, R., Demazières, A., et al.[2015]

References

Dual Orexin Receptor Antagonists (DORAs) as an Adjunct Treatment for Smoking Cessation. [2022]
Sleep as a Target for Optimized Response to Smoking Cessation Treatment. [2020]
Comparison of the effects of a 24-hour nicotine patch and a 16-hour nicotine patch on smoking urges and sleep. [2015]
Narcolepsy with cataplexy masked by the use of nicotine. [2021]
Tobacco withdrawal and nicotine replacement influence objective measures of sleep. [2019]
Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation. [2017]
The influence of 8 and 16 mg nicotine patches on sleep in healthy non-smokers. [2018]
[Cigarette smoking and sleep disturbance]. [2015]
Sleep changes in smokers before, during and 3 months after nicotine withdrawal. [2016]